2-CdA in the treatment of hairy cell leukemia: A review of long-term follow-up

Adi Gidron, Martin S. Tallman*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations

Abstract

Hairy cell leukemia is a rare, indolent, chronic lymphoproliferative disorder characterized by the proliferation of a malignant B-cell clone with irregular cytoplasmic projections. Treatment with purine analogs such as 2-chlorodeoxyadenosine (2-CdA) is associated with excellent remission rates and long-term survival. Although the majority of patients achieve a complete remission (CR), most have minimal residual disease detected by sensitive methods. Despite the long term disease-free survival, approximately 36% of patients relapse and many require further therapy. Repeat administration of 2-CdA is very effective in achieving a second CR. Recently, new agents such rituximab and BL22 were shown to be effective in the treatment of relapsed and refractory disease.

Original languageEnglish (US)
Pages (from-to)2301-2307
Number of pages7
JournalLeukemia and Lymphoma
Volume47
Issue number11
DOIs
StatePublished - Nov 2006
Externally publishedYes

Keywords

  • 2-CdA
  • Hairy cell leukemia
  • Purine analogs

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of '2-CdA in the treatment of hairy cell leukemia: A review of long-term follow-up'. Together they form a unique fingerprint.

Cite this